The current financial score of Cytosorbents Corp is 6.36. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 9.63M, representing a year-over-year increase of 0.17%, while its net profit experienced a year-over-year increase of 326.86%.
The current valuation score of Cytosorbents Corp is 9.14. Its current P/E ratio is -30.40, which is -96.14% below the recent high of -1.17 and -11.48% above the recent low of -33.89.
The current earnings forecast score of Cytosorbents Corp is 6.00. The average price target is 47.50, with a high of 80.00 and a low of 15.00.
The current price momentum score of Cytosorbents Corp is 7.93. Currently, the stock price is trading between the resistance level at 8.42 and the support level at 4.11, making it suitable for range-bound swing trading.
The current institutional shareholding score of Cytosorbents Corp is 3.00. The latest institutional shareholding proportion is 25.84%, representing a quarter-over-quarter decrease of 10.95%. The largest institutional shareholder is James Simons, holding a total of 100.02K shares, representing 0.00% of shares outstanding, with 84.75% decrease in holdings.
The current risk assessment score of Cytosorbents Corp is 1.73. The company's beta value is 1.37. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.